PHOX2B is a homeodomain-containing protein that is involved in the development of the peripheral nervous system and is the major disease gene for the rare congenital breathing disorder congenital central hypoventilation syndrome (CCHS). Germline PHOX2B alterations were also recently discovered in neuroblastoma cases with CCHS and/or Hirschsprung disease, but a comprehensive survey for mutational frequency and functional consequence has not been performed. We therefore studied a large panel of hereditary neuroblastomas to understand the frequency and functional effects of PHOX2B mutations. Three of 47 individuals with presumed genetic predisposition to neuroblastoma showed a germline PHOX2B mutation (6.4%). Mutations were also discovered in 2 of 30 human neuroblastoma-derived cell lines, but none of 86 primary tumors from patients with sporadically occurring neuroblastoma. The vast majority of primary tumors showed abundant PHOX2B mRNA expression relative to the remainder of the transcriptome. Consistent with its role as an important neurodevelopmental gene, forced overexpression of wild-type PHOX2B in neuroblastoma cell lines suppressed cell proliferation and synergized with all-trans retinoic acid to promote differentiation. Patient-derived mutant PHOX2B constructs retained the ability to suppress cellular proliferation, but were not able to promote differentiation or activate expression of a known PHOX2B target gene in vitro. These findings show that PHOX2B alterations are a rare cause of hereditary neuroblastoma, but disruption of this neurodevelopmental pathway can interfere with transcription-dependent terminal differentiation. These data also suggest that the genetics of neuroblastoma initiation are complex, and highlight genes involved in Introduction PHOX2B is a homeodomain-containing protein that is involved in the development of the autonomic nervous system. Mice engineered to be null for PHOX2B have deficits in the development of the central and peripheral nervous system, especially sympathetic ganglia (Pattyn et al., 1999) . Overexpression of PHOX2B in developing chick spinal cord promotes cell cycle exit and differentiation of neural crest cells (Dubreuil et al., 2000) , with the dopamine b-hydroxylase (DBH) promoter being one of the major transcriptional targets (Yang et al., 1998) . Taken together, it is clear that PHOX2B is a master regulator of neural crest cell lineage determination and/or maturation.
PHOX2B is also the major disease gene for congenital central hypoventilation syndrome (CCHS), a rare but often devastating disorder where infants have a lack of sympathetic nervous system-mediated respiratory drive (Amiel et al., 2003) . A subset of patients with CCHS also has other disorders of neural crest-derived tissues, such as Hirschsprung disease (HSCR) or neuroblastoma. Heterozygote germline alterations in PHOX2B have recently been identified in patients with familial neuroblastoma (Mosse et al., 2004; Trochet et al., 2004) . In addition, PHOX2B mutations have also been discovered in sporadic cases of neuroblastoma, usually (but not always) in association with HSCR and/or CCHS (van Limpt et al., 2004; McConville et al., 2006) .
Neuroblastoma is a pediatric cancer that usually occurs very early in life. It may be congenital, can be inherited, and some patients show more than one primary tumor. Thus, neuroblastoma is a genetic disease, but the mutational events that initiate the process remain largely unknown. We therefore performed a comprehensive survey for PHOX2B mutations in a carefully selected panel of patients with presumed genetic predisposition (family history and/or associated congenital anomalies and/or multifocal primary tumors). In addition, we used neuroblastoma cell models to investigate the functional consequences of PHOX2B mutations discovered in patients.
Results

Identification of PHOX2B sequence variants and mutations in human neuroblastoma
We screened 163 unique DNA samples from neuroblastoma patients for sequence alterations in the coding regions of the PHOX2B gene. We compared these data to DNA-sequencing results from a panel of 111 control subjects and relevant databases. A total of 14 sequence variations were detected in 34 samples (Table 1) . The majority of the sequence alterations were known synonymous base substitutions predicted to have no effect on the expressed protein. In addition, a variety of in-frame deletion variants were detected in the 3 0 portion of the gene, some of which were not previously reported or detected in our control set. Two DNA sequence variations predicted to alter the PHOX2B protein were detected in the panel of 30 cell lines. The SK-N-SH deletion was confirmed as previously reported (van Limpt et al., 2004) , and also detected in its SY5Y Denotes whether specimen was from patient with a known disorder of neural crest-derived tissues. None known, denotes cell lines with incomplete phenotype information. None, represents individuals where phenotyping information is complete and no associated neural crest disorder was diagnosed. HSCR/CCHS indicated when both disorders are present in the pedigree, not necessarily both in the proband. c Predicted functional change. No with '?' indicates that this is not proven. * indicates that the DNA sequence alteration was proven to have a functional consequence in this paper.
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EH Raabe et al subclone (not included in Table 1 ). A putative singlebase alteration was detected in IMR-5 that is predicted to change an amino acid. Both mutations occurred at residues conserved 100% across species (Figure 1 ). Unfortunately, phenotyping data for the patients from whom these cell lines were established are not complete, and we cannot determine if any of these patients had CCHS, HSCR or other comorbidities. Three germline mutations were detected in patients with presumed genetic predisposition to neuroblastoma (familial reoccurrence and/or associated disorder and/or multifocal primary tumors). As previously reported, the 676delG mutation segregates with the disease across three generations in Family 1 with CCHS and HSCR (proband alone also has a NF1 mutation) (Mosse et al., 2004) . A novel eight-base insertion/duplication was detected in the proband of a Family 36, and like Family 1 this mutation segregated with the disease in an affected parent and an unaffected aunt and also occurred coincident with CCHS and HSCR ( Figure 1 ). A patient with sporadic neuroblastoma and HSCR was shown to have a G299T (R100L) mutation in the DNA-binding domain, identical to a mutation discovered in a family with neuroblastoma and HSCR previously reported (Trochet et al., 2004) . No triplet expansion mutations predicted to extend either of the two polyalanine tracts were detected in any sample.
Only synonymous single-base substitutions were discovered in a screen of 86 sporadic neuroblastoma tumor DNAs in which the patients had no other known disorder of neural crest-derived tissues (Table 1) .
No mutations of PHOX2A in neuroblastoma cell lines We screened the same human neuroblastoma-derived cell line DNAs and 50 control DNA samples from the Coriell SNP500 Cancer Panel using standard PCR protocols. A novel heterozygous variation (c.465_473del9) was detected in cell line NMB and 2% of control alleles. No other alterations in PHOX2A were observed.
PHOX2B loss of heterozygosity is rare and does not correlate with mRNA expression status We screened the 86 primary neuroblastoma samples used in the mutational analyses for loss of heterozygosity (LOH) across the PHOX2B locus. Six samples (7.0%) showed LOH. Two samples from patients with metastatic disease at diagnosis showed breakpoints between markers D4S405 and D4S2971. The remaining samples showed LOH at all informative markers. These samples were also studied on a bacterial artificial chromosome array comparative genomic hybridization platform, which confirmed the deletions in each case, including a breakpoint (not disrupting PHOX2B) at 4p13 in two cases, whole chromosome loss in three cases, and 4p loss in the remaining case (data not shown, manuscript submitted). There was no correlation with PHOX2B allelic status or expression status as measured by microarray or quantitative reverse transcription (RT)-PCR . In fact, we noticed in these data that PHOX2B was highly expressed in the vast majority of diagnostic neuroblastoma samples. Only 1.23% of the 12 559 probe sets showed median expression values higher than PHOX2B across the sample set of 101 cases studied on the Affymetrix U95Av2 platform. PHOX2B was uniformly highly expressed across the sample set with approximately 40 Â higher mRNA copy number compared to human fetal brain (data available at www.ncbi.nlm.nih.gov/geo/ query/acc.cgi?acc ¼ GSE3960). Cloning and forced expression of wild-type and mutant PHOX2B Wild-type PHOX2B was cloned from human embryonal sympathetic chain ganglion cDNA and the G299T, and 676delG human mutations in PHOX2B were engineered using PCR-based techniques. We also engineered a mutant construct designed to be missing the entire homeodomain. Each variant construct was confirmed by direct sequencing. We first demonstrated that protein from each construct was expressed following transient transfection into neuroblastoma cell lines (Figure 2a) . We then determined cellular localization by immunohistochemistry. PHOX2B protein was localized to the nucleus in all assays except for the homeodomain deletion mutant, which also is missing a putative nuclear localization signal (Dingwall, 1991) (Figure 2b ).
Overexpression of wild-type PHOX2B and patientderived PHOX2B mutants decrease neuroblastoma growth velocity and proliferation To explore the hypothesis that PHOX2B functions as a neuroblastoma tumor suppressor, we next forcibly overexpressed wild-type and mutant PHOX2B proteins in SK-N-AS and NLF cells. These cells were chosen for the studies due to their rapid proliferation in vitro, biallelic wild-type PHOX2B status and resistance to cellular differentiation (Gaetano et al., 1991) , but discordant MYCN amplification status. Figures 2c and d show that overexpression of wild-type PHOX2B caused a significant decrease in logarithmic growth velocity in SK-N-AS and NLF cells as measured in a label-free real-time cell electronic sensing assay (RT-CES) (Atienza et al., 2006) . Somewhat surprisingly, patient-derived mutant PHOX2B constructs also showed a similar, but less profound, effect on phenotype, but the homeodomaindeleted (HDdel) mutant (presumably lacking DNA binding) showed no effect on cell index over time. Neither wild-type or mutant PHOX2B constructs showed a discernible difference in NGP cell proliferation using the RT-CES assay system (data not shown).
We next directly measured SK-N-AS proliferation in a standard BrdU incorporation assay (Figure 2e ). Similar to the RT-CES cell index data, wild-type and patient-derived mutant PHOX2B proteins suppressed SK-N-AS proliferation, while the HDdel mutant had an attenuated effect on cell proliferation. In the BrdU incorporation assay, there was a small, but statistically significant difference between the HDdel mutant-transfected and -untransfected conditions. This difference may represent the effect of overexpression of transfected message and resultant protein. Because of the nature of a double-label experiment, it is not possible to include an empty vector control, since the denaturing step required for BrdU visualization destroys the fluorescence of the green fluorescent protein (GFP), making identification of empty vector-transfected cells impossible. There was a larger, more statistically significant difference between HDdel mutant-transfected and all of the other PHOX2B constructs, indicating that a lack of nuclear localization of PHOX2B and of DNA binding largely attenuates PHOX2B's effect on cell proliferation.
Overexpression of PHOX2B promotes apoptosis in SK-N-AS cells
To investigate the mechanism of PHOX2B and PHOX2B mutant inhibition of cell proliferation in SK-N-AS cells, cell cycle distribution determination was performed by propidium iodide staining and flow cytometry. Forced overexpression of wild-type and patient-derived mutant PHOX2B vector constructs led to a large sub-2N population, but not when the HDdel construct was used as a control (Figure 2f ).
Mutant PHOX2B fails to transactivate a PHOX2B consensus promoter sequence We next sought to determine if mutations discovered in neuroblastoma patients might interfere with transcriptional activation of a known target gene. We chose NGP cell line for these studies because they show the lowest basal PHOX2B expression levels in the setting of no mutation and no allelic deletion. We performed transient cotransfection assays with a luciferase reporter construct containing the minimal promoter region of the DBH gene (Figure 3 ). Basal transactivation of the DBH promoter was observed following cotransfection of empty vector, presumably due to endogenous expression of PHOX2B (and perhaps PHOX2A). As expected, forced expression of wild-type PHOX2B enhanced DBH transactivation, but this was absent or largely attenuated in each of the mutant construct cotransfections.
PHOX2B mutations interfere with cellular differentiation NGP cells can be induced to differentiate with retinoids in a dose-dependent manner (unlike SK-N-AS, which are differentiation resistant). We therefore transfected NGP cells with wild-type and mutant PHOX2B constructs, and then selected for stable transfectants. Single colonies were obtained and shown to express approximately equal amounts of PHOX2B by anti-FLAG immunoblotting (data not shown). NGP cells stably overexpressing wild-type and mutant PHOX2B did not show any changes in cell cycle distribution or apoptosis as measured by flow cytometry (data not shown). Wild-type PHOX2B complemented the effect of all-trans retinoic acid (ATRA) on promoting cellular differentiation (Figure 4) . In contrast, each of the mutants had no additional effect on neurite outgrowth in the presence of ATRA.
Discussion
Neuroblastoma is an embryonal cancer of the sympathetic nervous system that typically occurs very early in life. There has been tremendous progress in defining somatically acquired genomic aberrations that are highly correlated with the clinical phenotype. For example, tumors with MYCN amplification, or with hemizygous deletions of chromosome arms 1p and/or 11q are typically metastatic at diagnosis and are difficult to cure (Attiyeh et al., 2005) . On the other hand, little is known about the genetic alterations that initiate neuroblastoma tumorigenesis. Embryonal cancers are unique because they are often congenital and therefore can be considered a phenotypic consequence of defective normal development. The genes regulating normal neural crest cell lineage specification and cell fate thus become candidates for neuroblastoma predisposition genes. Since PHOX2B is the first neurodevelopmental gene proven to harbor germline mutations in neuroblastoma patients, we performed a detailed analysis to understand the frequency and functional consequence of germline mutations specific to this disease.
Our data show that from a neuroblastoma population standpoint, PHOX2B mutations are rare. Only 2 of 30 neuroblastoma probands with a first-or second-degree relative also having neuroblastoma had PHOX2B mutations, and in both cases the phenotype was complex in that both CCHS and HSCR cosegregated with neuroblastoma. Only 1 of 17 highly selected patients with associated congenital disorders or clear multifocal tumors had a PHOX2B mutation, and again this patient had CCHS and HSCR. We found two mutations in neuroblastoma-derived cell lines (one previously described (van Limpt et al., 2004) ), and these may serve as good models for future functional investigations. We did not see any mutations in unselected primary neuroblastoma DNAs, consistent with the relatively low mutation frequency seen in other studies (van Limpt et al., 2004; McConville et al., 2006) . Taken together, our result that germline mutations of PHOX2B are rarely found even in cases with clear genetic predisposition is perhaps not surprising since published and ongoing genetic linkage analyses in our lab have not identified a major predisposition locus at 4p13, the chromosomal location of the PHOX2B gene (Maris et al., 2002) . These data suggest that PHOX2B mutations are likely an initiating event for neuroblastoma patients with a complex phenotype including other disorders of neural crest-derived tissues, but that these mutations rarely contribute to the formation of the majority of human neuroblastomas.
This work further extends the genotype-phenotype relationship previously noted for PHOX2B mutations. Whereas the majority of PHOX2B mutations in CCHS patients are triplet expansion mutations predicted to extend the second polyalanine tract in the C-terminal portion of the protein, mutations in neuroblastomas tend to be missense alterations in highly conserved regions or nonsense mutations that lead to a truncated protein and absent second polyalanine motif (Amiel et al., 2003; Weese-Mayer et al., 2003; Matera et al., 2004; Mosse et al., 2004; Trochet et al., 2004; van Limpt et al., 2004; McConville et al., 2006) . We therefore sought to understand how these neuroblastoma-specific mutations might influence tumorigenesis and whether PHOX2B might play a role in neuroblastoma progression in the absence of coding-region mutations.
One potential explanation for mutations in a bona fide tumor suppressor being relatively rare is haploinsufficiency of the protein being sufficient to promote tumorigenesis. We did not have matched tumor samples to look for deletion of wild-type allele in the few mutation carriers we detected, but the relative rarity of allelic deletion of the PHOX2B locus (7% of cases, most whole chromosome losses) argues against a gene dosage mechanism. Supporting this conclusion is our observation that PHOX2B mRNA is highly expressed in essentially all neuroblastomas. Indeed, PHOX2B was originally cloned out of the neuroblastoma cell line CHP-134 (Yokoyama et al., 1996) , shown to have biallelic wildtype sequence in this study. These data might suggest that neuroblastomas generally arise at a time when PHOX2B is normally expressed during neurodevelopment. In light of the fact that forced overexpression of wild-type PHOX2B in a neuroblastoma cell line (with basal PHOX2B expression) decreased proliferation, it appears most likely that PHOX2B expression in primary tumors is simply a marker of tumor lineage, not a contributor to the malignant phenotype. In this regard, PHOX2B may be a highly neuroblastoma-specific mRNA that could be exploited in any screening strategy based on RT-PCR for rare tumor cells in biological samples (Beiske et al., 2005) . Finally, it is possible that other genes involved in sympathetic nervous system development that interacts with PHOX2B might be mutated and phenocopy PHOX2B mutations. While we did not perform an exhaustive search, we at least demonstrated here that PHOX2A mutations are not common in neuroblastomas. Ongoing work is directed at a thorough resequencing of genes known to be involved in sympathicoadrenal development in addition to the PHOX2 gene family.
The PHOX2B mutations discovered in our sample set each encode proteins that are likely expressed (missense or C-terminal nonsense mutations). It is therefore possible that heterozygous mutations of PHOX2B result in dominant-negative protein, interfering with the normal PHOX2B protein expressed from the nonmutated allele. Unlike classic tumor suppressors, both wildtype and mutant PHOX2B slowed cellular proliferation and promoted apoptosis in our assays. In contrast, wildtype PHOX2B synergized the effect of ATRA on promoting neuroblastoma differentiation, while mutant proteins had no effect. Because the mutant proteins also failed to transactivate a known PHOX2B promoter, these data strongly suggest that PHOX2B is critical for normal terminal differentiation of neuroblasts through the transactivation of critical prodifferentiation genes. Mutant PHOX2B proteins, likely through a dominantnegative interaction, fail to transactivate these key downstream genes and abrogate the process of differentiation. Failure of committed neuronal precursors to undergo terminal differentiation could lead to cellular crisis and acquisition of new mutations that could promote tumorigenesis.
It is unclear why PHOX2B and the PHOX2B mutants characterized here have an effect on cell proliferation and apoptosis in SK-N-AS and NLF cells, but not in NGP cells. It may be that NGP, as a more differentiation-competent cell line, can tolerate high levels of exogenous PHOX2B expression, while SK-N-AS, as a differentiation-resistant cell line that is also wild-type for p53 and pRB, cannot differentiate and is pushed toward apoptosis by overexpressed PHOX2B. The different effects of PHOX2B depending on the cell context and the role of PHOX2B in promoting apoptosis are areas of active investigation in our laboratory.
In summary, our data clearly demonstrate that missense and nonsense mutations in the PHOX2B gene can provide a heritable predisposition to a complex phenotype of neuroblastoma and/or CCHS and/or HSCR. These data add to a growing body of evidence that the genetics of neuroblastoma initiation are complex and it is likely that oligogenic or polygenic interactions are necessary for tumor initiation. These data also highlight the fact that neuroblastoma may result from the misappropriation of normal developmental pathways, and that defects in cell maturation/ differentiation can be cancer predisposing.
Materials and methods
Samples and DNA sequencing Bidirectional sequencing and LOH analyses of PHOX2B are detailed in the Supplementary Information. PHOX2B mRNA expression Affymetrix U95Av2 data were abstracted from the publicly available dataset generated in our lab as previously reported . PHOX2B expression was also measured by quantitative RT-PCR using AB assays-on-demand primer sequences.
DNA constructs and transfection
Full-length human PHOX2B was cloned by RT-PCR and inserted into either pIRES2-GFP vector (Clontech, Palo Alto, CA, USA) or pcDNA3.1 vector (Invitrogen, Carlsbad, CA, USA). Altered transcripts were produced to recapitulate human mutations by PCR-based mutagenesis and an HDdel PHOX2B was engineered to contain an in-frame deletion of the homeodomain region, spanning nucleotides 265-508 (amino acids 89-169). A 5 0 or 3 0 FLAG epitope tag was inserted into the constructs to allow identification of recombinant protein.
Cell growth and proliferation using the RT-CES assay SK-N-AS cells were transfected with PHOX2B constructs, selected for 5 days in 1 mg/ml neomycin and then plated in RTCES microelectronic sensor arrays (ACEA Biosciences, San Diego, CA, USA) for 72 h. Cell density measurements were made every 30 min. Cell density was normalized to the 6 h time point.
BrdU incorporation, luciferase and differentiation assays Details are found in the Supplementary Information. Briefly, SK-N-AS cells were transiently transfected with PHOX2B constructs, incubated in normal media for 72 h and then pulsed with BrdU for 6 h. At least 300 FLAG-positive cells were counted for each condition. Luciferase assays were performed 48 h following transfection. NGP (differentiation susceptible) cells were transfected with PHOX2B constructs, selected using 1 mg/ml neomycin and then cylinder cloned. These stable clones were then exposed for 3 weeks to 5 mM ATRA or control vehicle (ethanol), and cells with neurites longer than two cell bodies in length were counted. 
